Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentan [0.03%]
用于免疫球蛋白A肾病患者的nefecon或sparsentan治疗的匹配调整间接比较肾脏功能研究
Christopher Ngai,Mit Patel,Agnieszka Kopiec et al.
Christopher Ngai et al.
Aim: We compared the effects of nefecon, an oral targeted-release budesonide formulation, and sparsentan, an oral, dual endothelin-angiotensin receptor antagonist, on estimated glomerular filtration rate (eGFR) in patients with immunoglobul...
Association of liver biomarker values beyond current thresholds and negative clinical outcomes in primary biliary cholangitis: analysis of a real-world healthcare claims database [0.03%]
肝生物标志物值超出当前阈值的原发性胆汁性胆管炎患者预后不良的临床结局：来自真实世界医疗数据库的分析
Timothy E Ritter,Christina J Hanson,Christopher Fernandes et al.
Timothy E Ritter et al.
Aim: To assess the predictive effect of threshold deviations for multiple liver biomarkers on negative clinical outcomes, including hepatic decompensation, liver transplantation, and death in patients with primary biliary cholangitis (PBC) ...
Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with advanced non-small-cell lung cancer in China [0.03%]
在中国对晚期非小细胞肺癌患者进行PD-L1检测以指导免疫治疗的成本效益分析
Fei Zhou,Yuan Li,Jian Ming et al.
Fei Zhou et al.
Aim: This study aims to assess the cost-effectiveness of three major programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) testing assays in guiding immunotherapy for patients with advanced non-small-cell lung cancer (NSCLC) in China...
Access in all areas? A round-up of developments in market access and health technology assessment: part 11 [0.03%]
处处有通路？市场准入和卫生技术评估的发展现状：第11部分
Sreeram V Ramagopalan,Annie Jullien Pannelay,Jo Atkins
Sreeram V Ramagopalan
In this update, we cover the evolving health technology assessment process in Australia and also examine how commercial health plans in the US influence patient access to treatments. ...
Bridging the patient gap: exploring generative AI to support meaningful patient involvement in health technology assessment [0.03%]
弥合患者差距：探索生成式人工智能以支持健康技术评估中患者的有意义参与
Manuel Cossio,Ramiro E Gilardino
Manuel Cossio
Patient and public involvement in health technology assessment (HTA) has progressed from best practice to policy requirement, yet communication barriers persist. This perspective explores how plain language summaries (PLSs) and summaries of...
Letter to the Editor - Qualitative evidence submitted by patients to NICE: need for more quality or unrealistic and unfair requirements? [0.03%]
致编辑的信：患者提交给NICE的定性证据：需要更高的质量还是不切实际和不公平的要求？
Rocco Falchetto,Jasmin Barman-Aksözen
Rocco Falchetto
Letter in Reply - Quality in qualitative evidence: new best practice principles from NICE's real-world evidence framework [0.03%]
关于NICE真实世界证据框架中的质量质性证据：新的最佳实践原则的回应信件
Vandana Ayyar Gupta,Sarah Scott,Mandy Tonkinson et al.
Vandana Ayyar Gupta et al.
Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2 [0.03%]
使用真实世界数据模拟随机对照试验的考量：来自MONALEESA-2研究的启示
Amanda M Kong,Dionna Andrean,Saarah Khan et al.
Amanda M Kong et al.
Aim: The eligibility criteria of randomized controlled trials can exclude groups of patients indicated for the therapy post-approval and the trial population may not be generalizable to routine care. We attempted to emulate the MONALEESA-2 ...
Real-world evidence of pimavanserin utilization among patients with Parkinson's disease psychosis: a review of real-world data that augments data from randomized controlled trials [0.03%]
帕金森病精神病患者使用吡莫申的真实世界证据：对随机对照试验数据的补充性真实世界数据分析综述
Nazia Rashid,Ismaeel Yunusa,Dilesh Doshi et al.
Nazia Rashid et al.
Aim: Pimavanserin (PIM) is the only US FDA-approved atypical antipsychotics (AAPs) for the treatment for hallucinations and delusions associated with Parkinson's disease psychosis (PDP). In addition to demonstrating symptom improvements in ...
R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 22 [0.03%]
一石二鸟：真实世界证据在支付与准入中的应用及面临挑战（下）
Paul Arora,Sreeram V Ramagopalan
Paul Arora
In this update, we examine the growing potential of synthetic data in addressing data access challenges for health technology assessment. We explore studies evaluating synthetic data as external control arms in clinical trials and the appli...